Searchable abstracts of presentations at key conferences in endocrinology

ea0026p462 | Thyroid cancer | ECE2011

A case of calcitonin and CEA negative medullary thyroid carcinoma

Kovacs G L , Denes J , Hubina E , Kovacs L , Lahm E , Kosa R , Voros A , Goth M

Background: The most reliable biochemical markers in the follow-up of medullary thyroid carcinoma (MTC) are serum calcitonin (CAL) and carcinoembrional antigen (CEA).Case: A 82 years male presented with rapidly growing neck tumour in April 2008. The patient underwent total thyroidectomy with lymph node dissection (June 2008). The pathology revealed MTC localized only in the left lobe (pT3NoMx), the immunohistology showed CAL-, synaptophysin, chromogranin...

ea0022p241 | Clinical case reports and clinical practice | ECE2010

Macroprolactinoma after chronic buserelin treatment in patient with prostate cancer

Laszlo Ferenc A , Gervain Mihaly , Voros Erika , Molnar Andor H , Laszlo Ferenc

Twelve years following hemicolectomy for colon adenocarcinoma, a 75-year-old patient with prostate cancer was treated for 4 weeks with the antiandrogen nilutamide and then with the long-acting GnRH agonist buserelin. The serum testosterone and prostate-specific antigen (PSA) levels had decreased dramatically after 3 months of treatment. After 2 years of buserelin administration, the hormonal state was examined. Serum estradiol, testosterone, DHEA, DHEAS, FSH and LH levels prov...